Cytomed granted Malaysian patent for CAR-gamma delta T cell technology

CytoMed Therapeutics announced that the Intellectual Property Corporation of Malaysia has granted a patent for its chimeric antigen receptor, CAR, gamma delta T cell technology which targets solid and hematological tumors. The patent titled “Gamma Delta T Cells and a Method of Augmenting the Tumoricidal Activity of the Same” covers technologies for the clinical-scale expansion of gammadelta T cells from a small amount of donor peripheral blood cells, as well as the modification of the expanded gammadelta T cells to incorporate a chimeric antigen receptor that enables the modified cells to recognize a wide range of cancers, including both solid and hematological cancers. The Company holds an exclusive, worldwide license to use this patent pursuant to the License Agreement dated June 1, 2018, filed with the Securities and Exchange Commission as an exhibit to the registration statement on Form F-1 on March 30, 2023. “With the commencement of our first in-human clinical trial for CAR-gammadelta T cells in Singapore, we are pleased that our technology is granted a patent in Malaysia where our operational PIC/S GMP facility is situated,” said Peter Choo, Chairman of CytoMed. “This grant adds to the breadth of our tumor-targeting therapy patent portfolio, alongside a US patent and Chinese patent in respect of this CAR T technology. This patent grant is timely as Malaysia is attracting more biomedical innovators amidst an ageing population and reputation as a medical tourism hub.”